Skip to main content
Premium Trial:

Request an Annual Quote

Study Experimentally Validates Compugen's Computationally Predicted Drug Target for Multiple Myeloma

Premium

This story originally ran on May 11.

Israeli drug and diagnostics discovery firm Compugen said today that it has completed initial experimental validation for membrane protein CGEN-928 as a drug target for the treatment of multiple myeloma.

The company said that the protein's expression profile indicates that it might also be useful as a diagnostic and prognostic marker for multiple myeloma.

Compugen said that it first identified CGEN-928 as a potential target through its computational technology, called the Monoclonal Antibody Targets Discovery Platform, which predicted that the protein would demonstrate high expression levels in multiple myeloma samples compared to normal tissue.

The recently completed studies confirmed that CGEN-928 does show broad expression in human multiple myeloma tumor cells, including drug-resistant and primary tumor cell lines. Compugen said that it has filed patent applications covering the use of CGEN-928 for these and additional therapeutic and diagnostic purposes.

"These early results obtained with CGEN-928 are very encouraging, especially given the fact that this protein is showing high levels of expression in many multiple myeloma tumors that are very drug resistant and highly aggressive," James Berenson, medical and scientific director of the Institute for Myeloma & Bone Cancer Research — where much of the study was conducted — said in a statement.

A malignancy of the bone marrow, multiple myeloma is the second most common blood cancer after non-Hodgkin's lymphoma. It represents roughly 1 percent of all cancers and 2 percent of all cancer deaths.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.